Literature DB >> 24668442

Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms.

J Y Jang1, T Park, S Lee, M J Kang, S Y Lee, K B Lee, Y R Chang, S W Kim.   

Abstract

BACKGROUND: Classifications of intraductal papillary mucinous neoplasm (IPMN) remain ambiguous, especially for the mixed type. Factors predicting malignancy remain unclear. The aim of this study was to evaluate the usefulness of factors predicting malignancy in the new international consensus guidelines for resection of branch duct-type (BD)-IPMN and to compare them with those in the previous version.
METHODS: A prospectively collected database of patients with biopsy-proven BD-IPMN was analysed to compare factors between the first and second consensus guidelines, particularly as predictors of malignancy.
RESULTS: Of 350 patients with BD-IPMN, sensitivity (0.724) and balanced accuracy (0.751) of the second guidelines were superior to those (0.639 and 0.730) in the first version at the expense of slightly reduced specificity (0.779 versus 0.822 for the first version) by random forest models. Multiple logistic regression analysis showed that main pancreatic duct dilatation greater than 5 mm (hazard ratio (HR) 4.54, 95 per cent confidence interval 2.45 to 8.41; P < 0.001), mural nodules (HR 6.27, 3.27 to 12.01; P < 0.001) and carbohydrate antigen 19-9 level above 37 units/ml (HR 4.03, 1.83 to 8.90; P = 0.001) were independent predictors of BD-IPMN malignancy.
CONCLUSION: The new consensus guidelines provide better sensitivity, performance of factors predicting malignancy, and balanced accuracy in the diagnosis of BD-IPMN malignancy. Size alone was limited in predicting malignancy. Variability in clinical significance of the individual factors associated with a risk of malignancy indicates the need for a tailored approach in the management of patients with BD-IPMN.
© 2014 BJS Society Ltd. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668442     DOI: 10.1002/bjs.9491

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  35 in total

1.  Comparison between MRI with MR cholangiopancreatography and endoscopic ultrasonography for differentiating malignant from benign mucinous neoplasms of the pancreas.

Authors:  Jiyoung Hwang; Young Kon Kim; Ji Hye Min; Woo Kyung Jeong; Seong Sook Hong; Hyun-Joo Kim
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  Validation of the American Gastroenterological Association guidelines on management of intraductal papillary mucinous neoplasms: more than 5 years of follow-up.

Authors:  Koh Imbe; Naoyoshi Nagata; Yuya Hisada; Yusuke Takasaki; Katsunori Sekine; Saori Mishima; Akihito Kawazoe; Tsuyoshi Tajima; Takuro Shimbo; Mikio Yanase; Junichi Akiyama; Kazuma Fujimoto; Naomi Uemura
Journal:  Eur Radiol       Date:  2017-08-02       Impact factor: 5.315

3.  Circulating Leptin and Branched Chain Amino Acids-Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade.

Authors:  Michele T Yip-Schneider; Rachel Simpson; Rosalie A Carr; Huangbing Wu; Hao Fan; Ziyue Liu; Murray Korc; Jianjun Zhang; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

4.  Surgical outcomes of multifocal branch duct intraductal papillary mucinous neoplasms of pancreas.

Authors:  Jae Hyun Kwon; Song Cheol Kim; Ki-Byung Song; Jae Hoon Lee; Dae Wook Hwang; Kwang-Min Park; Young-Joo Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2014-11-30

5.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

Review 6.  Diagnosis and management of pancreatic cystic neoplasms.

Authors:  Mathew James Keegan; Bharat Paranandi
Journal:  Frontline Gastroenterol       Date:  2019-03-01

7.  Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.

Authors:  Rachel E Simpson; Michele T Yip-Schneider; Katelyn F Flick; Huangbing Wu; Cameron L Colgate; C Max Schmidt
Journal:  Pancreas       Date:  2019-09       Impact factor: 3.327

8.  Evaluation of the International Consensus Guidelines for the Surgical Resection of Intraductal Papillary Mucinous Neoplasms.

Authors:  Mariko Tsukagoshi; Kenichiro Araki; Fumiyoshi Saito; Norio Kubo; Akira Watanabe; Takamichi Igarashi; Norihiro Ishii; Takahiro Yamanaka; Ken Shirabe; Hiroyuki Kuwano
Journal:  Dig Dis Sci       Date:  2017-06-30       Impact factor: 3.199

Review 9.  [Branch duct intraductal papillary mucinous neoplasm - surgical approach].

Authors:  J Kaiser; M W Büchler; T Hackert
Journal:  Chirurg       Date:  2017-11       Impact factor: 0.955

10.  Rapid Growth Rates of Suspected Pancreatic Cyst Branch Duct Intraductal Papillary Mucinous Neoplasms Predict Malignancy.

Authors:  Wilson T Kwong; Robert D Lawson; Gordon Hunt; Syed M Fehmi; James A Proudfoot; Ronghui Xu; Andrew Giap; Raymond S Tang; Ingrid Gonzalez; Mary L Krinsky; Thomas J Savides
Journal:  Dig Dis Sci       Date:  2015-04-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.